When does Avadel report earnings and how could that affect AVDL stock?

Avadel reports earnings on **2026-03-09**. The print and guidance could swing AVDL stock strongly, especially if management updates progress on FT218 or revenue guidance deviates from expectations.

What valuation metrics matter most for AVDL stock?

Investors focus on price-to-sales **8.55**, price-to-book **21.39**, and free cash flow per share **0.36**. These show a premium valuation that needs clinical and commercial validation to hold.

What is Meyka AI's short-term AVDL stock forecast?

Meyka AI's forecast model projects a monthly target of **$20.63**, implying **-4.67%** from the current price. Forecasts are model outputs and not guarantees.

What are the top risks for AVDL stock ahead of earnings?

Top risks include a weak Phase 3 update, disappointing commercial traction, and valuation compression. Any negative signals on FT218 or guidance could pressure AVDL stock.

US Stocks

AVDL stock closes at $21.64 on 03 Mar 2026: earnings Mar 9 set next catalyst

ByDanny Kontos March 4, 2026March 4, 2026

AVDL stock closed at $21.64 on NASDAQ in the United States after a quiet session on 03 Mar 2026. We see the next major catalyst as Avadel Pharmaceuticals plc (AVDL) earnings due Mar 9, 2026, and the ongoing Phase 3 FT218 program remains central to investor expectations. Trading showed heavy volume at 35,016,239 shares versus an average of 2,415,222, which signals elevated investor attention ahead of the report. We examine valuation, technicals, and the Meyka AI forecast to frame likely market reactions.